Cabaletta Bio Ends Sales Agreement with TD Securities

Cabaletta Bio ( (CABA) ) has issued an update.

On June 11, 2025, Cabaletta Bio announced the termination of a Sales Agreement with TD Securities, which previously allowed for the sale of up to $200 million in shares, with no penalties incurred. Concurrently, Cabaletta presented new clinical data from its RESET trials at the EULAR 2025 Congress, showcasing promising results for rese-cel in treating myositis, lupus, and systemic sclerosis. The data indicated significant clinical responses in patients, supporting the potential of rese-cel to change treatment paradigms for autoimmune diseases.

The most recent analyst rating on (CABA) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Cabaletta Bio stock, see the CABA Stock Forecast page.

Spark’s Take on CABA Stock

According to Spark, TipRanks’ AI Analyst, CABA is a Underperform.

Cabaletta Bio’s overall score is low primarily due to its financial performance, marked by no revenue and increasing losses. The technical analysis indicates a bearish trend, further impacting the score. However, the recent positive clinical trial data provides a glimmer of hope, slightly improving future outlook. Despite this, the stock’s valuation remains a concern, making it a risky investment at this stage.

To see Spark’s full report on CABA stock, click here.

More about Cabaletta Bio

Cabaletta Bio is a clinical-stage biotechnology company focused on developing and launching curative targeted cell therapies specifically for patients with autoimmune diseases. The company is advancing the discovery and development of engineered T cell therapies, with its lead strategy prioritizing rese-cel, a CD19-CAR T cell investigational therapy, evaluated in the RESET clinical development program across multiple therapeutic areas, including rheumatology, neurology, and dermatology.

Average Trading Volume: 1,433,604

Technical Sentiment Signal: Sell

Current Market Cap: $119.2M

Learn more about CABA stock on TipRanks’ Stock Analysis page.